Investigational drug · Phase 3
LEN FDC
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HIV-1-infection, HIV-1 Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
10
Any phase or sponsor naming "LEN FDC"
First trial start
2021
Oct 5, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LEN FDC", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV-1-infection
- HIV-1 Infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "LEN FDC" as an intervention, largest first.
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502341 · 689 participants · Start Aug 16, 2022 · Primary completion Sep 29, 2025
Drug: Bictegravir; Lenacapavir and 2 more · For: HIV-1-infection
Sites: Berkeley, California; Beverly Hills, California; Los Angeles, California · 94 sites in all
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06333808 · 577 participants · Start Mar 25, 2024 · Primary completion Oct 27, 2025
Drug: Bictegravir/Lenacapavir (BIC/LEN) FDC; Lenacapavir and 4 more · For: HIV-1-infection
Sites: Phoenix, Arizona; Berkeley, California; Beverly Hills, California · 104 sites in all
- Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIVPivotal-lookingNot yet recruiting
Gilead SciencesGilead Sciences (GILD)
NCT07908446 · 400 participants (planned) · Start Nov 2026 · Primary completion Jul 2028
Drug: BIC/LEN FDC; Lenacapavir and 1 more · For: HIV-1 Infection
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)Pivotal-lookingRecruiting
Taiho Oncology, Inc.Industry
NCT04256317 · 316 participants (planned) · Start May 21, 2020 · Primary completion Nov 1, 2027
Drug: Azacitidine; ASTX030 (cedazuridine + azacitidine) and 4 more · For: Myelodysplastic Syndromes; Acute Myeloid Leukemia; Myelodysplastic Syndrome/Neoplasm and 1 more
Sites: Los Angeles, California; Orange, California; New Haven, Connecticut · 73 sites in all
- Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06513312 · 268 participants · Start Oct 7, 2024 · Primary completion May 28, 2026
Drug: Lenacapavir Injection; Lenacapavir Tablet and 1 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Bobigny, France; Marseille, France; Nice, France · 14 sites in all
- Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06101329 · 253 participants · Start Nov 17, 2023 · Primary completion Jul 22, 2026
Drug: Lenacapavir Tablet; Lenacapavir Injection and 1 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Birmingham, Alabama; San Diego, California; Washington D.C., District of Columbia · 11 sites in all
- Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT04143594 · 183 participants · Start Nov 22, 2019 · Primary completion Oct 5, 2021
Drug: Oral Lenacapavir; F/TAF and 4 more · For: HIV-1-infection
Sites: Phoenix, Arizona; Los Angeles, California; Palm Springs, California · 53 sites in all
- Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06101342 · 181 participants · Start Dec 13, 2023 · Primary completion Jul 27, 2026
Drug: Lenacapavir Injection; Lenacapavir Tablet and 1 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Los Angeles, California; San Diego, California; Miami, Florida · 9 sites in all
- Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05052996 · 142 participants · Start Oct 5, 2021 · Primary completion Dec 19, 2023
Drug: ISL; LEN and 2 more · For: HIV-1 Infection
Sites: Beverly Hills, California; Los Angeles, California; Newport Beach, California · 44 sites in all
- Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06532656 · 75 participants (planned) · Start Nov 20, 2024 · Primary completion Jul 2030
Drug: Lenacapavir; Bictegravir/Lenacapavir (BIC/LEN) FDC and 1 more · For: HIV-1-infection
Sites: Washington D.C., District of Columbia; Tampa, Florida; Atlanta, Georgia · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HIV-1-infection
- GS-3242Phase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- OBRPhase 32 trials
Gilead Sciences · HIV-1-infection
- TMB-365TMB-380, VRC07523LSPhase 23 trials
TaiMed Biologics Inc. · HIV-1-infection, HIV -1 Infection
- CAP256V2LSPhase 21 trial
Gilead Sciences · HIV-1-infection
- PirmitegravirPhase 21 trial
ST Pharm Co., Ltd. · HIV-1-infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.